Citi: retatrutide data raises the competitive bar for Novo Nordisk
Citi kept a neutral/high-risk rating on Novo after the retatrutide results, judging tolerability broadly similar to Ozempic on nausea but with more diarrhoea and discontinuations.
Source: Proactive Investors (29 Oct 2026). Image: Proactive Investors.